Cancer Commons founder Marty Tenenbaum, Ph.D., will speak at the upcoming Precision Medicine World Conference (PMWC) in Silicon Valley, which runs Jan 22–24. Marty, who founded Cancer Commons after his own battle with melanoma, will discuss the potential for artificial intelligence to help find better cancer treatments. Read the synopsis of Marty’s presentation, entitled “How AI will Cure Cancer”: From an AI perspective, finding effective treatments for cancer… Read more »
In a new guest blog post for CollabRx, Cancer Commons scientist and project manager Lisandra West-Odell discusses how we’re harnessing the power of data analytics to improve treatment for cancer patients, starting with brain cancer: “I am reminded of the old adage: ‘Lessons come from the journey, not the destination.’ Where one patient’s story can only exist as an anecdote, many stories can be… Read more »
Hear from some more cancer fighters: Avid @ArizonaCoyotes fan Tom (Labonte) from Chandler and @judefox10 #YotesFightCancer pic.twitter.com/LVlQ0Z7NW0 — FOX Sports Arizona (@FOXSPORTSAZ) November 5, 2017 Fox 10 News sports anchor Jude LaCava is a long-time proponent of Cancer Commons who has sent many patients and caregivers our way to receive extra guidance for their cancer treatment, including Super Patient Mary Beth Smith. This past weekend,… Read more »
We at Cancer Commons express our deep gratitude to the H8 Cancer Foundation, which has generously made our organization a major beneficiary of its gifts since 2015. Founded by oncologist Dr. Simeon Jaggernauth, H8 Cancer is “dedicated to raising funds for research and to promote awareness of better treatment options to save lives.” Recently, we had the honor of attending Tomstock, an annual summer music festival to benefit H8… Read more »
Cancer Commons founder Marty Tenenbaum wrote a letter to the editor that has now been published in The Economist. His piece discusses the importance of using data to accelerate improvement of cancer treatment. From the letter: “The oncology drug pipeline is full of promising immunotherapies and targeted treatments (Technology Quarterly on cancer, September 16th). Unfortunately, no one knows the optimal way to use them. Doctors and patients… Read more »
A little more than four years ago, longtime friends Tom and Carman Duvall, and Kiers and Steve Rowley reminisced at dinner about their lives in the 1980s, long before their schedules had grown complicated and filled with endless trips driving children to various activities. Tom, a child of 1980s rock and roll, wondered aloud whether Def Leppard might perform for them on his next… Read more »
In 2014, a dedicated team of Deloitte colleagues joined forces to help cancer patients find the best treatment options for optimal outcomes. They made their first gifts to Cancer Commons in memory of Jackie Tran. Ms. Tran was a Deloitte partner who received support from Cancer Commons’ ASK service while navigating her treatment options for ovarian cancer. Since then, over $300,000 has been raised… Read more »
Cancer Commons provides expert, personalized guidance to patients and caregivers around the world through our ASK Cancer Commons service. Recently, we plotted the distribution of our ASK users on a world map to see where they live. We found that about 2,000 people in more than 44 countries have sought help from Cancer Commons. “Cancer Commons is catering to an international audience and therefore… Read more »
A new article from BioQuick News discusses Cancer Commons founder Marty Tenenbaum’s presentation at last week’s Personalized Medicine World Conference: In the PMWC 2017 discussion, Dr. Tenenbaum focused on the question: When faced with certain death, is it acceptable to accept less than 100% proven safety and efficacy? Patients with glioblastoma and certain other cancers with dire prognoses do not have the time to… Read more »
In a recent Xconomy article on cancer DNA testing, Cancer Commons medical director Kevin Knopf shares his perspective: “To help all patients we think an open-source database has the most utility,” says Knopf. Instead of current tests that list a patient’s mutations and potential drugs to use, a report should rank therapies the way online travel sites rank best options. Read the full article… Read more »
Image credit: